PCC0208017 is a novel Inhibitor of MARK3/MARK4, Suppressing Glioma Progression in vitro and in vivo. In vitro,PCC0208017 strongly inhibited kinase activity against MARK3 and MARK4, and strongly reduced prolifer-ation in three glioma cell lines. PCC0208017 attenuated glioma cell migration, glioma cell invasion, andangiogenesis. PCC0208017 decreased the phosphorylation ofTau, disrupted microtubule dynamics, and induced a G2/M phase cell cycle arrest. In aninvivoglioma model,PCC0208017 showed robust anti-tumor activity, bloodebrain barrier permeability, and a good oral pharma-cokinetic profile.
MedKoo Cat#: 534234
Name: PCC0208017
CAS#: 2623158-64-3
Chemical Formula: C19H20F3N7
Exact Mass: 403.1732
Molecular Weight: 403.41
Elemental Analysis: C, 56.57; H, 5.00; F, 14.13; N, 24.30
The following data is based on the product molecular weight 403.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
